Shares of Ultragenyx lost nearly half their value after the company’s experimental drug for Angelman syndrome — a rare neurogenetic disorder with no approved treatment — failed a pivotal trial.
The drug, GTX-102 (apazunersen), missed both its primary and secondary endpoints in the Phase 3 ASPIRE study. The company was blunt: “There were no differences between the treated and control groups that could support efficacy.” Angelman syndrome affects brain and body function; many patients cannot walk or speak and need lifelong care.
The fallout
GTX-102 had carried peak-sales estimates of $1.8 billion or more — so its failure is a major blow. Ultragenyx said it will evaluate the program’s future and is pursuing “significant expense reductions,” targeting profitability in 2027 after earlier layoffs and restructuring. One analyst said the company’s wording “leaves very little room for an optimistic interpretation,” and that Ultragenyx has shifted from a “pipeline execution story” to a “commercial and expense story.”
Why it matters
Rare-disease drug development is high-risk, and a single Phase 3 miss can reset a company’s trajectory. For Angelman families waiting on a first treatment, it’s a painful setback; for Ultragenyx, it forces a pivot toward its remaining pipeline (including UX111 for Sanfilippo syndrome) and tighter spending.